MedTrace Logo

Phase III Copanlisib in Rituximab-refractory iNHL

NCT02369016 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-11-18

Study results available
· View outcomes & findings →

Summary

To assess the safety of copanlisib.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

DRUG

Copanlisib (BAY 80-6946)

60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-22
Primary Completion
2022-10-26
Completion
2022-10-26

Countries

  • Brazil
  • Bulgaria
  • Greece
  • Italy
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02369016 on ClinicalTrials.gov